Ketoprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. Aloxiprin may increase the hypoglycemic activities of Insulin Aspart. Polythiazide may increase the hypotensive activities of Tetrahydropalmatine. The risk or severity of adverse effects can be increased when Natamycin is combined with Niguldipine. The risk or severity of adverse effects can be increased when Ramipril is combined with Tolmetin. Balsalazide may decrease the antihypertensive activities of Penbutolol. The metabolism of Darunavir can be decreased when combined with Clotrimazole. The metabolism of Perospirone can be decreased when combined with Losartan. The serum concentration of Everolimus can be increased when it is combined with Vinblastine. The metabolism of Flurazepam can be decreased when combined with Darunavir. Oxprenolol may increase the hypoglycemic activities of Gliclazide. The metabolism of Hexobarbital can be decreased when combined with Imatinib. The risk or severity of adverse effects can be increased when Tolnaftate is combined with Lercanidipine. Stiripentol may increase the sedative activities of Ethanol. Phenelzine may increase the hypotensive activities of Dihydralazine. The metabolism of Doxazosin can be decreased when combined with Terbinafine. Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin. The metabolism of Verapamil can be decreased when combined with Isoniazid. The risk or severity of adverse effects can be increased when Artesunate is combined with Dapsone. Foscarnet may increase the nephrotoxic activities of Neomycin. Salicylamide may decrease the antihypertensive activities of Carteolol. Carbaspirin calcium may decrease the excretion rate of Daunorubicin which could result in a higher serum level. The serum concentration of Cholecalciferol can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Alclofenac is combined with Betamethasone. The serum concentration of Diclofenac can be increased when it is combined with Simeprevir. The metabolism of Yohimbine can be decreased when combined with Sulfisoxazole. The risk or severity of adverse effects can be increased when Spironolactone is combined with Nadolol. The metabolism of Levonorgestrel can be increased when combined with Phenobarbital. Clonidine may increase the hypotensive activities of Tolazoline. Trimethoprim may increase the hyperkalemic activities of Perindopril. The risk or severity of adverse effects can be increased when Nitroprusside is combined with Prazosin. The risk or severity of adverse effects can be increased when Pentolinium is combined with Oxycodone. BL-1020 may increase the hypotensive activities of Dextropropoxyphene. The risk or severity of adverse effects can be increased when Trandolapril is combined with Chlorothiazide. Tromethamine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin. The risk or severity of adverse effects can be increased when Nabumetone is combined with Betamethasone. The metabolism of Eletriptan can be decreased when combined with Pargyline. Indomethacin may increase the anticoagulant activities of Nadroparin. The risk or severity of adverse effects can be increased when Isradipine is combined with Mannitol. Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. The risk or severity of adverse effects can be increased when Tiotropium is combined with Fentanyl. The metabolism of Lidocaine can be decreased when combined with Felodipine. Aloxiprin may increase the anticoagulant activities of Ancrod. The metabolism of Nilvadipine can be increased when combined with Amobarbital. Estrone sulfate may increase the hypokalemic activities of Hydroflumethiazide. The risk or severity of adverse effects can be increased when Fosinopril is combined with Nafamostat. The serum concentration of Methoxsalen can be increased when it is combined with Osimertinib. The metabolism of Clonidine can be decreased when combined with Tenofovir disoproxil. Niflumic Acid may increase the anticoagulant activities of Antithrombin III human. The serum concentration of Nisoldipine can be decreased when it is combined with Pentobarbital. The serum concentration of Salmeterol can be increased when it is combined with Atazanavir. The risk or severity of adverse effects can be increased when Artemether is combined with Tetrahydropalmatine. Diazoxide may increase the hypotensive activities of Cicletanine. The metabolism of Vismodegib can be decreased when combined with Sulfisoxazole. The metabolism of Levodopa can be decreased when combined with Methadone. Proscillaridin may decrease the cardiotoxic activities of Ofloxacin. Ritonavir may increase the QTc-prolonging activities of Goserelin. Levofloxacin may increase the anticoagulant activities of Phenindione. The risk or severity of adverse effects can be increased when Amobarbital is combined with Chloral hydrate. The serum concentration of Rilpivirine can be increased when it is combined with Fosamprenavir. The serum concentration of Benzoic Acid can be increased when it is combined with Probenecid. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Edrophonium. The risk or severity of adverse effects can be increased when Mizoribine is combined with Tixocortol. The therapeutic efficacy of Latanoprost can be decreased when used in combination with Antipyrine. The serum concentration of Tinidazole can be decreased when it is combined with St. John's Wort. The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Oxymetazoline. The risk or severity of adverse effects can be increased when Metoprolol is combined with Perindopril. Azelastine may increase the anticoagulant activities of Ancrod. The risk or severity of adverse effects can be increased when Irbesartan is combined with Nitroaspirin. The serum concentration of Everolimus can be increased when it is combined with Meprobamate. The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estrone. The risk or severity of adverse effects can be increased when Bromfenac is combined with Tenofovir disoproxil. The risk or severity of adverse effects can be increased when Radicicol is combined with Dapsone. Reserpine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. The metabolism of Levobupivacaine can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Pirbuterol. The serum concentration of Triamcinolone can be decreased when it is combined with St. John's Wort. The serum concentration of Enfuvirtide can be increased when it is combined with Simeprevir. Aclidinium may increase the ulcerogenic activities of Potassium Chloride. The risk or severity of adverse effects can be increased when Ketorolac is combined with Fenoprofen. Parthenolide may decrease the antihypertensive activities of Bevantolol. The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quinapril. The metabolism of Brompheniramine can be decreased when combined with Betaxolol. The metabolism of Tacrolimus can be decreased when combined with Amphotericin B. The metabolism of Triamcinolone can be decreased when combined with Imatinib. The metabolism of Diazepam can be decreased when combined with Cobicistat. The risk or severity of adverse effects can be increased when Dyclonine is combined with Methadyl Acetate. Benzydamine may decrease the excretion rate of Gentamicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Ergonovine is combined with Cocaine. The risk or severity of adverse effects can be increased when Artemether is combined with Lacidipine. The risk or severity of adverse effects can be increased when Aceprometazine is combined with Opium. The metabolism of Caffeine can be decreased when combined with Terbinafine. The serum concentration of Prasterone can be increased when it is combined with Fosaprepitant. Orciprenaline may increase the hypokalemic activities of Chlorthalidone. The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diclofenac. Pentobarbital may increase the hypotensive activities of Benazepril. Amobarbital may increase the sedative activities of Pramipexole. Alclometasone may increase the fluid retaining activities of Methyltestosterone. The serum concentration of Artemether can be increased when it is combined with Darunavir. The metabolism of Pioglitazone can be decreased when combined with Isradipine. The metabolism of Phenprocoumon can be decreased when combined with Darunavir. The serum concentration of Mestranol can be decreased when it is combined with Enalapril. Salicylic acid may increase the anticoagulant activities of Ancrod. The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Acetaminophen. Salmeterol may increase the QTc-prolonging activities of Perflutren. The metabolism of Aliskiren can be increased when combined with Rifapentine. Benazepril may increase the orthostatic hypotensive activities of Levodopa. Spironolactone may decrease the vasoconstricting activities of Synephrine. The metabolism of Regorafenib can be decreased when combined with Darunavir. The serum concentration of Rosuvastatin can be increased when it is combined with Ritonavir. Etofenamate may increase the neuroexcitatory activities of Levofloxacin. Brimonidine may increase the antihypertensive activities of Unoprostone. The risk or severity of adverse effects can be increased when Nabilone is combined with Dapagliflozin. The serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b. The serum concentration of Rilpivirine can be increased when it is combined with Dronedarone. The serum concentration of Indomethacin can be increased when it is combined with Luliconazole. Flumethasone may increase the hypokalemic activities of Metolazone. The therapeutic efficacy of Iobenguane can be decreased when used in combination with Procaterol. The risk or severity of adverse effects can be increased when Eprosartan is combined with Tolmetin. The risk or severity of adverse effects can be increased when Quinapril is combined with Oxaprozin. Tadalafil may increase the antihypertensive activities of Pindolol. The risk or severity of adverse effects can be increased when Benzocaine is combined with Oxprenolol. The metabolism of Darifenacin can be decreased when combined with Ritonavir. The therapeutic efficacy of Folic Acid can be decreased when used in combination with Parecoxib. Dorzolamide may increase the hypotensive activities of Manidipine. The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Temsirolimus. Selegiline may increase the hypotensive activities of Amlodipine. The therapeutic efficacy of Miglitol can be decreased when used in combination with Betamethasone.